A.B. Pharma

Shanghai AB Pharma Tech Ltd (AB Pharma) is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of novel small molecule therapeutics for oncology and metabolic diseases. Founded in 2014 by Dr. Zhengyun Zhan, the company leverages advanced medicinal chemistry to develop multi-target tyrosine kinase inhibitors (TKIs) and treatments for unmet medical needs in cancer, diabetes, and obesity. Its lead oncology candidate, ABP1011T, is currently in Phase 2 clinical trials for advanced solid tumors and osteosarcoma, while its metabolic program, ABP2111, is being evaluated for the treatment of obesity. AB Pharma also maintains a pipeline of dual-target therapies for Hepatitis C and other metabolic disorders.